Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
camrelizumab + apatinib + pemetrexed + carboplatin
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination therapy consists of the anti-PD-1 monoclonal antibody camrelizumab, the VEGFR2-selective tyrosine kinase inhibitor apatinib, and a standard chemotherapy doublet of pemetrexed and carboplatin. It is being investigated by The First Affiliated Hospital of Xiamen University for the treatment of patients with ALK-positive advanced non-squamous non-small cell lung cancer (NSCLC) who have progressed on or failed prior tyrosine kinase inhibitor (TKI) therapy. Apatinib (marketed as Aitan) acts as an antiangiogenic agent by inhibiting tumor blood vessel formation, while camrelizumab (marketed as AiRuiKa) enhances the immune system's ability to detect and destroy tumor cells. The addition of chemotherapy aims to provide cytotoxic effects and potentially synergize with the immunotherapy and antiangiogenic components. This Phase II single-arm clinical trial evaluates the efficacy and safety of this quadruple combination approach in a population with limited treatment options after TKI resistance.
- Brand names
- AiRuiKaAitan
- Other names
- Camrelizumab + Apatinib + Pemetrexed + CarboplatinCamrelizumab + Apatinib + Chemo
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)GART (GAR transformylase)TS (Thymidylate synthase)VEGFR2 (Vascular endothelial growth factor receptor 2)DNADHFR (Dihydrofolate reductase)
Beyond the preview
Go deeper on camrelizumab + apatinib + pemetrexed + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on camrelizumab + apatinib + pemetrexed + carboplatin.